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Purpose: There is growing agreement that definitions of “recovery” in bipolar-I disorder
(BP-I) should include functional outcomes beyond sustained symptomatic remission. In this
post-hoc analysis, we assessed functional recovery rates according to the validated
Functioning Assessment Short Test (FAST) in participants with BP-I after 52 weeks of
maintenance treatment with aripiprazole once monthly (AOM).
Patients and methods: Rates of functional recovery with AOM 400 were investigated in two
52-week studies. NCT01567527 was a placebo-controlled, double-blind, randomized-withdrawal
study and NCT01710709 was an open-label study. Functional recovery, assessed at the end of the
respective maintenance phases, was defined as a total FAST score of ≤11 for 8 consecutive weeks.
Results: Post-hoc analyses included 229 patients from the randomized-withdrawal study
(AOM 400 n=116; placebo n=113). The open-label study included 402 patients (including
321 de novo patients and 81 rollover patients who had completed the randomized-withdrawal
study). In the randomized-withdrawal study, functional recovery was achieved by 30.2%
(n=35) of the AOM 400 group compared with 24.8% (n=28) in the placebo group. The
difference was not statistically significant (p=0.39). In the open-label study, 36% (n=116) of
de novo patients and 43% (n=35) of rollover patients had functionally recovered after 52
weeks of AOM 400 treatment.
Conclusion: These data highlight the utility of a sustained FAST total score of ≤11 as a
definition of recovery and emphasize the possibility of achieving this ambitious treatment
goal with effective long-term treatment.
Keywords: bipolar disorder, aripiprazole, long-acting injectable, maintenance, functioning,
recovery
Plain language summary
Functional recovery is beginning to be considered equally as important as symptomatic
recovery in patients with bipolar I disorder (BP-I). We present post-hoc analyses of two
studies in which we assessed functional recovery rates according to the validated Functioning
Assessment Short Test (FAST) in participants with BP-I after 52 weeks of maintenance
treatment with aripiprazole 400 mg once monthly (AOM). To our knowledge, this is the first
analysis of clinical trials to use the FAST scale as a definition of functional recovery, and we
show that 30–43% of patients achieved functional recovery after 52 weeks’ maintenance
treatment with AOM.
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Introduction
While many people living with bipolar disorders regain
psychosocial functioning upon symptomatic remission, the
majority suffer persistent functional difficulties, often
despite adequate control of their core affective symptoms.
Such functional deficits include problems in their ability to
work, study, live independently, maintain interpersonal
relationships and participate in recreational activities.1
Mood stabilizers and/or atypical antipsychotics are well
accepted as the mainstays of bipolar-I disorder (BP-I)
treatment.2–4 Compared with their oral counterparts, long-
acting injectable (LAI) atypical antipsychotic formulations
allow for better adherence with more consistent dosing2,4
and have recently shown to be more effective in preventing
hospitalization of BP-I patients due to mental or physical
illness.5 Aripiprazole 400 mg once monthly (AOM 400) is
an LAI approved by the US Food and Drug Administration
as maintenance monotherapy treatment for BP-I.6 Results
from recent placebo-controlled7 and open-label8 studies
show that maintenance treatment with AOM 400 delays
the time to mood episode recurrence and is safe and well-
tolerated.
There is growing agreement that definitions of “func-
tional recovery” in bipolar disorders should include func-
tional outcomes beyond sustained symptomatic remission.9
Both studies of AOM 400 as maintenance treatment used the
Functioning Assessment Short Test (FAST), which was
developed as a short simple interview-administered instru-
ment for use in patients with psychiatric disorders, and espe-
cially bipolar disorders.10 The FAST has been shown to have
strong psychometric properties and is able to detect differ-
ences between euthymic and acute patients with bipolar
disorder.10 We have previously reported maintenance of
improvement in FAST scores over 52 weeks in the AOM
group of the placebo-controlled study.11 Taking into account
the FAST cut off scores proposed by Rosa et al,10 we defined
recovery as a FAST total score ≤11 for ≥8 consecutive weeks
and assessed the rates of functional recovery in participants
with BP-I after long-term (52-week) treatment with
AOM 400.
Materials and methods
The efficacy and safety of AOM 400, given every 4 weeks,
as maintenance treatment of BP-I was investigated in two,
52-week studies, the full methodologic details of which
have been previously published:
1. A placebo-controlled, double-blind, randomized-
withdrawal study (NCT01567527) conducted in
103 sites in 7 countries.7
2. An open-label, multicenter study (NCT01710709)
conducted in 149 sites in 10 countries.8
Both studies7,8 were conducted in compliance with the
Declaration of Helsinki and International Conference on
Harmonization Good Clinical Practice guidelines for con-
ducting, recording and reporting trials, as well as for
archiving essential documents. Consistent with ethical
principles for the protection of human research subjects,
no trial procedures were performed on trial candidates
until written consent had been obtained from them. The
informed consent form , protocol and amendments for
this trial were submitted to and approved by the institu-
tional review board (IRB) or independent ethics commit-
tee (IEC) for each respective trial site or country
(Table S1).
Study design
Study designs are summarized in Figure 1. Briefly, in the
randomized-withdrawal study, participants completed
oral aripiprazole conversion and stabilization phases if
needed, followed by a single-blind AOM 400 stabiliza-
tion phase. Those meeting stability criteria (outpatient
status, Young Mania Rating Scale [YMRS] total score
≤12, Montgomery–Asberg Depression Rating Scale
[MADRS] total score ≤12 and no active suicidality)
were randomized to double-blind treatment with AOM
400 or placebo for 52 weeks.
The open-label study had two protocols, depending on
whether the participants were de novo or had rolled-over
from the randomized-withdrawal study. Whereas rollover
participants began the 52-week, open-label AOM 400 main-
tenance phase immediately after completing the prior dou-
ble-blind maintenance phase (AOM400 or placebo), de novo
participants entered a 4- to 12-week oral aripiprazole stabili-
zation phase before entering the open-label maintenance
phase. If de novo participants were receiving a non aripipra-
zole antipsychotic medication before enrollment, a 4- to 6-
week oral aripiprazole cross-titration phase was implemented
before the oral aripiprazole stabilization phase.
Participants
Both studies enrolled outpatients (18–65 years) who had a
clinical diagnosis of BP-I (DSM, 1994), and who were further
verified by the Mini-International Neuropsychiatric Interview.
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Participants included in the open-label study were rolled over
from the double-blind study or were AOM 400 treatment-
naive and enrolled de novo.
All participants in the randomized-withdrawal study and
new participants recruited to the open-label studywere eligible
for the trial if they had experienced ≥1 previous manic or
mixed episode with manic symptoms of sufficient severity to
require hospitalization, treatment with a mood stabilizer, or
treatmentwith an antipsychotic agent. Study entry criteriawere
similar, except that the randomized-withdrawal study required
participants to have a YMRS score >20 and excluded partici-
pants with a mixed or depressive episode, and the open-label
study had no YMRS criterion and only excluded participants
with a depressive episode. The open-label study also included
rollover participants, who had completed the maintenance
phase of the randomized-withdrawal study (AOM 400 or
placebo) without recurrence of a mood episode. Participants
previously on placebo had prior exposure to AOM 400 due to
the 12- to 28-week AOM 400 stabilization phase.
Analysis of functional recovery
These analyses included all participants (both studies) who
received maintenance study treatment and had ≥1 post base-
line FAST assessment. Functioning was assessed using the
FAST (Table S2), where trained investigators ranked the
participant’s level of difficulty from 0 (no difficulty) to 3
(severe difficulty). Domains are based on grouping of the 24
individual items: autonomy (4 items), occupational func-
tioning (5 items), cognitive functioning (5 items), financial
issues (2 items), interpersonal relationships (6 items) and
leisure time (2 items). The FAST total score (range 0–72) is
calculated as the sum of each of the 24 item scores, with
higher scores representing worse function.10 Any one miss-
ing score led to a missing total score. In addition, our
definition included a minimum duration of 8 consecutive
weeks to ensure that transient fluctuations were not desig-
nated as recovery.12
Functional recovery was thus defined post-hoc as a FAST
total score of ≤11 for 8 consecutive weeks. FAST total and
domain scores (LOCF)were summarized at baseline andWeek
52 of the respective maintenance phases using mean and SD
for 1) all participants included in the analyses of FASTdata and
2) those participants who met criteria for functional recovery.
Between-group differences were derived from an ANOVA
model with treatment and region as baseline factors.
Results
Patient disposition and baseline
characteristics
Of the 266 participants entered into the randomized-
withdrawal phase of the placebo-controlled study, 116
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aPatients were stabilized for a manic episode prior to randomization; therefore recurrences of manic episodes were expected to predominate during the study. bpatients were switched to
oral aripiprazole if not already receiving it. cthe target dose in the oral stabilization phase was 15-30mg/day.dthe AOM-400 stabilization phase was single blind; if patients were stable for 8
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Figure 1 Study design. (A) Randomized-withdrawal study (Calabrese et al, 2017)7, (B) open-label maintenance study (Calabrese et al, 2018a).8
Abbreviation: AOM 400, Aripiprazole 400mg once-monthly.
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≥1 post-baseline FAST assessment. In the open-label
study, 402 of the original 464 participants entering the
maintenance phase had ≥1 post baseline FAST assess-
ment (321 de novo participants, 81 rollover partici-
pants). Overall 52/81 of the rollover participants had
already received treatment with AOM 400 for up to 52
weeks at baseline in the placebo-controlled, double-
blind study (for these participants total treatment dura-
tion, therefore, ranged between 52 and 80 weeks).
Baseline characteristics for the full populations of
the two studies have been previously published. In
brief, 57.5% of participants (n=266) in the rando-
mized-withdrawal study were female, the mean±SD
age was 40.6 ± 11.0 years and age at first manic
episode was 25.0 ± 10.1 years; participants had 3.5 ±
4.0 prior hospitalizations for a mood episode. The
mean YMRS total score was 2.8 ± 3.3, MADRS
score was 2.7 ± 3.4 and FAST score was 15.4 ± 12.7
(Phase D baseline).7 For the open-label study, 57.8% of
participants (n=464) were female, the mean age was
41.1 ± 11.8 years and age at first BP-I diagnosis was
29.1 ± 11.7 years. The mean YMRS total score was 2.3
± 2.9 and MADRS score was 3.2 ± 3.2.8
Rates of functional recovery
During the maintenance phase of the placebo-controlled, dou-
ble-blind study, 30.2%of participants (35/116) receivingAOM
400 and 24.8% of participants (28/113) receiving placebo
achieved FAST recovery. Recovery rates were not statistically
significant between AOM 400 and placebo groups (p=0.3944
[Cochrane–Mantel–Haenszel General Association Test
Controlling Region]). Of the participants who met recovery
criteria in the double-blind phase, 33 (n=23 previously treated
with AOM 400 and n=10 previously treated with placebo)
agreed to “roll-over” into the subsequent open-label study.
In the open-label study, functional recovery as mea-
sured by FAST after 52 weeks of treatment was achieved
by 36% of de novo participants (n=116) (Figure 2).
Overall, 43% of rollover participants (35/81) met the cri-
teria for functional recovery. This included 20 participants
who had previously received AOM 400 and met criteria
for functional recovery in the double-blind study and who
remained recovered after completing the following open-
label study (ie, they remained recovered into their second
year). An additional 5 participants had not met criteria for
functional recovery with AOM 400 during the placebo-
controlled study but achieved functional recovery in the
open-label study, while 3 participants were considered to
meet functional recovery criteria in the placebo-controlled
study but not in the open-label study. Of the participants
previously on placebo, 10 met criteria for functional
recovery with open-label AOM 400, including 8 who
met criteria for recovery in both studies.
FAST scores
In the randomized-withdrawal study, FAST total scores
were generally maintained in the group of participants
who received AOM 400 (mean±SD score of 15.92 ±
13.19 at baseline and 16.59±13.98 at last visit) and were
worsened in the placebo group (14.82 ± 12.12 at baseline
and 20.91 ± 16.87 at Week 52). The mean [95% CI]



































Figure 2 FAST recovery rates after long-term treatment with AOM 400 or placebo.
Abbreviations: FAST, Functioning Assessment Short Test; AOM 400, Aripiprazole 400 mg once monthly.
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−0.44] at Week 52 was statistically significant (p=0.028).
For those participants who met criteria for functional
recovery, mean ± SD FAST total scores numerically
improved from 5.47 ± 5.50 at baseline to 3.51 ± 3.62 at
Week 52 in the AOM 400 group and from 4.44 ± 4.23 at
baseline to 2.75 ± 2.86 at Week 52 in the placebo group.
Analyses by domain are provided in Table 1.
In the open-label study, de novo participants signifi-
cantly improved from a mean of 17.90 ± 13.51 at baseline
to 14.02 ± 12.02 at the end of the 4- to 12-week stabiliza-
tion phase (p<0.00001, one-sided Z test). FAST total
scores were then maintained during the 52-week mainte-
nance phase (from 14.02 ± 12.02 to 13.98 ± 13.05 in de
novo participants and from 12.89 ± 12.22 to 13.95 ± 13.46
in rollover participants). For those participants who met
criteria for functional recovery, mean FAST total scores
(baseline of maintenance phase/Week 52) were 4.09 ±
4.00/3.59 ± 3.39 in the de novo group and 3.71 ± 3.00/
3.54 ± 3.35 in the rollover group.
Discussion
To the best of our knowledge, this is the first analysis of
clinical trials to use FAST thresholds as a definition of
functional recovery and highlight the scale’s utility in
understanding the effectiveness of an intervention. Our
analyses of two long-term studies demonstrate that main-
tenance treatment with AOM 400 can help patients living
with BP-I achieve long-term functional recovery. Overall,
30–43% of participants who received AOM 400 for at
least 52 weeks achieved long-term functional recovery as
determined by a FAST score of ≤11 for at least 8 conse-
cutive weeks.
Although the threshold for recovery used in these ana-
lyses was initially based on the FAST validation studies,
which found that a score of >11 offers the best discrimi-
nant sensitivity and specificity,10 more recent studies sup-
port its use as a relatively conservative definition.
According to Bonnin et al, euthymic BP-I outpatients in
this category “present good functioning in all areas, they
live independently, they work and they have a meaningful
social engagement”.13 In terms of recovery rates, our
exploratory analyses of the randomized-withdrawal study
did not show statistical separation from placebo. This is
likely due, in part, to a survivor effect of the study design,
where participants who initially had marked functional
improvement and then stabilization (over 12–28 weeks)
were able to remain functionally recovered, even when
later randomized to placebo. Nevertheless, as previously
reported, participants randomized to placebo showed a
significant worsening in FAST scores relative to AOM
and a higher risk of relapse.11
Overall, at least 57% of the participants who met
criteria for functional recovery with AOM 400 mainte-
nance treatment during the placebo-controlled study (and
87% of those who also chose to “roll over” to open-label
treatment) remained recovered after completing the subse-
quent open-label study (ie, after 2 years of stable treat-
ment). Of note, a small proportion of participants did not
meet functional recovery criteria with active maintenance
treatment during the first year, but did during the second
year, thus supporting the idea that functional recovery
takes longer to achieve than symptom recovery.14 Here,
it is important to acknowledge that the entire rollover
subgroup was highly enriched for patients who responded
to and tolerated AOM treatment (during the stabilization
phase for placebo patients and during the stabilization plus
maintenance phases for AOM 400 patients). Indeed, due to
the enriched discontinuation study designs, the general-
izability of all results presented herein is limited to
patients experiencing a manic episode and stabilized on
AOM 400.
In terms of the maintenance effect (in both studies),
there were only small changes in domain scores, with all
functional domains remaining relatively stable with AOM
400 treatment. Likewise, all FAST domains appeared to
remain similarly stable in the subgroup of participants who
had functionally recovered. Subgroup analyses of the func-
tionally “recovered” participants showed that mean FAST
total scores were already <6 at baseline of the maintenance
phase, which is similar to a control group of participants
without bipolar disorder (mean of 5.93).15 The rates of
functional recovery seen with long-term AOM treatment
are in line with or slightly higher than those previously
reported after 52 weeks of olanzapine treatment.16
However, it should also be noted that the olanzapine
study defined functional recovery using a combination of
the psychosocial functioning sub scale of the SF-36 and
work status and disability support measures – the compar-
ability of which with the validated FAST scale is
unknown.
Limitations of this study include the post-hoc nature of
the recovery rate analyses and the lack of a blinded com-
parator in the open-label study. Whereas the minimum
duration of 8 consecutive weeks could be considered rela-
tively short,9 we based our definition to be consistent with
the recommendations of the International Society for
Dovepress Madera et al
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Table 1 FAST scores at baseline and Week 52 of each study (LOCF)
Randomized-withdrawal study Open-label AOM 400
maintenance study
AOM 400 Placebo Treatment effect (AOM vs placebo); LS mean [95% CI] De novo Rollover
Autonomy score
Total population
Baseline; mean (SD) 1.47 (2.07) 1.35 (2.10) −0.67 [−1.35,0.02] 1.23 (1.89) 1.19 (2.07)
Week 52; mean (SD) 1.72 (2.49) 2.43 (3.19) P=0.055 1.19 (1.46) 1.46 (2.27)
Recovery population
Baseline; mean (SD) 0.29 (0.63) 0.04 (0.19) 0.01 [−0.23,0.24] 0.28 (0.79) 0.26 (0.78)
Week 52; mean (SD) 0.17 (0.45) 0.11 (0.42) P=0.958 0.24 (0.60) 0.34 (0.94)
Occupational functioning score
Total population
Baseline; mean (SD) 5.73 (4.91) 5.69 (5.35) −0.82 [−1.88,0.24] 4.69 (4.69) 4.42 (5.18)
Week 52; mean (SD) 5.29 (4.91) 6.39 (5.54) P=0.128 4.50 (4.69) 5.05 (5.26)
Recovery population
Baseline; mean (SD) 2.26 (2.74) 1.56 (1.89) 0.24 [−0.63,1.11] 1.15 (1.85) 0.97 (1.32)
Week 52; mean (SD) 1.14 (1.65) 0.93 (1.59) P=0.582 1.04 (1.83) 0.91 (1.38)
Cognitive functioning score
Total population
Baseline; mean (SD) 3.28 (3.38) 2.91 (3.18) −0.56 (−1.44,0.32] 2.97 (2.99) 2.69 (3.20)
Week 52; mean (SD) 3.64 (3.62) 4.21 (4.06) P=0.212 2.00 (3.14) 2.86 (3.42)
Recovery population
Baseline; mean (SD) 0.97 (1.57) 0.96 (1.29) 0.32 [−0.12,0.76] 1.14 (1.38) 0.97 (1.67)
Week 52; mean (SD) 0.66 (1.21) 0.29 (0.66) P=0.155 0.96 (1.42) 0.86 (1.50)
Financial issues score
Total population
Baseline; mean (SD) 1.20 (1.66) 1.17 (1.48) −0.35 [−0.74,0.04] 1.17 (1.59) 0.93 (1.40)
Week 52; mean (SD) 1.16 (1.53) 1.57 (1.72) P=0.075 1.09 (1.58) 1.09 (1.49)
Recovery population
Baseline; mean (SD) 0.32 (0.68) 0.57 (1.23) −0.06 [−0.49,0.36] 0.40 (0.90) 0.31 (0.76)
Week 52; mean (SD) 0.29 (0.83) 0.43 (0.88) P=0.777 0.41 (0.95) 0.31 (0.76)
Interpersonal relationships score
Total population
Baseline; mean (SD) 2.84 (3.50) 2.45 (2.87) −1.32 [−2.32,-0.31] 2.75 (3.33) 2.52 (3.38)
Week 52; mean (SD) 3.15 (3.82) 4.50 (4.67) P=0.011 2.71 (3.63) 2.33 (3.62)
Recovery population
Baseline; mean (SD) 1.15 (1.62) 0.71 (1.01) 0.17 [−0.37,0.70] 0.67 (1.09) 0.66 (1.21)
Week 52; mean (SD) 0.77 (1.26) 0.46 (0.79) P=0.537 0.50 (1.01) 0.63 (1.03)
Leisure time score
Total population
Baseline; mean (SD) 1.40 (1.57) 1.18 (1.28) −0.19 (−0.58,0.20) 1.27 (1.44) 1.14 (1.40)
Week 52; mean (SD) 1.62 (1.65) 1.81 (1.76) P=0.339 1.45 (1.62) 1.16 (1.45)
Recovery population
Baseline; mean (SD) 0.47 (1.08) 0.50 (0.64) −0.00 [−0.38,0.38] 0.46 (0.78) 0.54 (0.89)
Week 52; mean (SD) 0.49 (0.92) 0.54 (0.69) P=0.992 0.44 (0.86) 0.49 (0.82)
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Bipolar Disorders for symptomatic recovery.12 While
LOCF analyses can be criticized, we used the same meth-
ods of imputation as per the primary study analyses.7,8
Although the roll over group provided important insights
into the longevity and time course of functional recovery,
it is important that almost half (47.6%) of the participants
who met criteria for functional recovery in the double-
blind phase did not choose to “roll over” to the open-
label trial. Finally, it has been recently suggested that
euthymic patients can be categorized into three main func-
tional types, low-, intermediate- and high-functioning, and
that the low- and intermediate-functioning types have
higher subthreshold depressive/manic symptoms and
worse cognition, particularly in terms of processing
speed.17 Future studies including patients with depression
as well as cognitive assessments may lend further clarity
to the predictors of long-term functional recovery with
AOM 400.
Conclusion
Functional recovery is beginning to be considered equally
as important as symptomatic recovery, since key goals for
patients and relatives are to fulfill role expectations at
work/school and home and to maintain good
relationships.18–20 Almost all individuals with bipolar dis-
orders require maintenance treatment to prevent subse-
quent episodes, reduce residual symptoms and restore
functioning.4 The results of this study demonstrate the
utility of a FAST total score of ≤11 for 8 consecutive
weeks as a definition of functional recovery in BP-I and
highlight the possibility of achieving this ambitious treat-
ment goal with effective treatment.
Ethics approval and informed
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Supplementary materials
Table S1 The Functioning Assessment Short Test (FAST)
Physician rates each item according to difficulty:
(0) None (1) mild (2) moderate (3) severe
AUTONOMY
1. Taking responsibility for a household
2. Living on your own
3. Doing shopping
4. Taking care of yourself (physical aspects, hygiene)
FINANCIAL ISSUES
15. Managing your own money
16. Spending money in a balanced way
OCCUPATIONAL FUNCTIONING
5. Holding down a paid job
6. Accomplishing tasks as quickly as necessary
7. Working in the field in which you were educated
8. Occupational earnings
9. Managing the expected workload
INTERPERSONAL RELATIONSHIPS
17. Maintaining a friendship or friendships
18. Participating in social activities
19. Having good relationships with people close to you
20. Living together with your family
21. Having satisfactory sexual relationships
22. Being able to defend you interests
COGNITIVE FUNCTIONING
10. Ability to concentrate on a book, film
11. Ability to make mental calculations
12. Ability to solve a problem adequately
13. Ability to remember newly-learned names
14. Ability to learn new information
LEISURE TIME
23. Doing exercise or participating in sport
24. Having hobbies or personal interests
Note: Data from Rosa et al (2007).10
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